Aethlon Medical (NASDAQ:AEMD) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their price objective on shares of Aethlon Medical from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, June 24th.

Aethlon Medical Stock Performance

Shares of AEMD opened at $0.47 on Friday. The business’s 50-day moving average is $0.39 and its two-hundred day moving average is $0.77. The company has a market capitalization of $6.48 million, a P/E ratio of -0.10 and a beta of 1.72. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.40.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.10. During the same period last year, the firm posted ($1.30) earnings per share. Analysts forecast that Aethlon Medical will post -1.1 EPS for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.